Feasibility and Effectiveness of tDCS in the Treatment of Post-stroke Fatigue (EFECTS).

Stroke Clinical Trial

— EFECTS  

Official title:

Feasibility and Effectiveness of Tdcs in a Multimodal Treatment With Health Education and Aerobic Exercise in the Treatment of Post-stroke Fatigue.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06149897
• Other study ID #: HCB/2022/1193
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 10, 2023
• Est. completion date: December 5, 2025

Study information

• Verified date: November 2023
• Source: Hospital Clinic of Barcelona
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to analyze the use of non-invasive brain stimulation (tDCS) is beneficial for the treatment of post-stroke fatigue.

Description:

A single-blind randomized clinical trial will be conducted. The intervention will consist of 8 20-minute tDCS sessions conducted over four weeks. The stimulation will be performed by applying the stimulation to the dorsolateral prefrontal cortex on the left side (F3) and the cathode will be at point O2 of the right hemisphere. The study will consist of two groups: the control group in which sham stimulation will be applied and therapeutic education and aerobic exercise; the intervention group in which stimulation, therapeutic education and therapeutic exercise will be carried out.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 54
• Est. completion date: December 5, 2025
• Est. primary completion date: December 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• First stroke within 45 (+-7) days of the ischemic or hemorrhagic episode.
• Ability to understand and execute simple instructions
• Over 18 years.
• Fatigue Scale of fatigue severity with a score greater than or equal to 24

Exclusion Criteria:

• A score > 2 on the modified Rankin Scale (mRS) before the stroke.
• Patients with decompensated cardiorespiratory and/or psychiatric pathology.
• Comorbidity causing disproportionate fatigue, such as long-term COVID.
• Patients who are cancer survivors or who are undergoing cancer treatment.
• Patients with a history of epilepsy or who are taking antiepileptic medication.
• Patents with major depression.

Related Conditions & MeSH terms

• Fatigue
• Stroke

Intervention

Device:
• tDCS
Non invasive brain stimulation with sham and active comparators

Locations

Country	Name	City	State
Spain	Hospital Clínic de Barcelona	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Clinic of Barcelona

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fatigue Assessment Scale	The scale consists of 10 questions about the characteristics of fatigue in the current daily routine, which are rated on a five-point range from 1, "never," to 5, "always." Higher scores indicate more fatigue, with a cut-off point of =24 defining the presence of fatigue.	Baseline, 1 month post intervention and 3 months post intervention. Reported through study completion, an average of 1 year.
Primary	HADS	It is a scale that can be used both at the hospital and outpatient level. It consists of 14 questions: 7 questions related to depression and another 7 related to anxiety. An independent score on each scale of = 8 will be suggestive of depression and/or anxiety.	Baseline, 1 month post intervention and 3 months post intervention. Reported through study completion, an average of 1 year.
Secondary	National Institute of Health Stroke Scale	It is a scale with 15 items that is used to measure the severity of stroke. It includes different areas: level of consciousness, eye movements, integrity of visual fields, facial movements, muscle strength, sensitivity, coordination, language and negligence. Each item is scored on an ordinal scale from 0 to 2, 0 to 3 or 0 to 4. The total is added and a score is obtained that can range from 0 to 42, the higher the score, the greater the deficits.	Baseline. Reported through study completion, an average of 1 year.
Secondary	Borg Modified Scale	The Borg scale is a tool that measures a person's perception of exertion, shortness of breath, and fatigue during physical exertion. It is a modified scale, it is an 11-point scale that ranges from 0=no fatigue to 10=very great effort.	During the sessions. Reported through study completion, an average of 1 year.
Secondary	PROMIS-Sleep	This is a Likert-type scale that evaluates the quality of sleep during the last week. Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance.	Baseline, 1 month post intervention and 3 months post intervention. Reported through study completion, an average of 1 year.
Secondary	Modified Rankin Scale	It is the most commonly used functional measure in stroke research, particularly in studies evaluating the effectiveness of treatments. The scale is numerical and ranges from 0 to 6. 0: no symptoms; 1: without significant disability (the patient is able to carry out his/her usual activities and obligations); 2: mild disability; 3: moderate disability; 4: moderately severe disability; 5: severe disability (totally dependent patient); 6: death.	Baseline, 1 month post intervention and 6 months post intervention. Reported through study completion, an average of 1 year.
Secondary	International Physical Activity Questionnaire (IPAQ)	To measure the level of physical activity during the last week. There are two forms of output from scoring the IPAQ. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). MET minutes represent the amount of energy expended carrying out physical activity. A MET is a multiple of your estimated resting energy expenditure. One MET is what you expend when you are at rest. Therefore 2 METS is twice what you expend at rest. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS.	Baseline, 1 month post intervention and 3 months post intervention. Reported through study completion, an average of 1 year.
Secondary	Eq-5D	Assess the quality of life perceived by the patients. The scale ranges from 100 ('the best imaginable health state' or 'the best health state you can imagine') to 0 ('the worst imaginable health state' or 'the worst health you can imagine'). This is used to obtain a respondent's stated preference values, not to record their own health state.	Baseline, 1 month post intervention and 3 months post intervention. Reported through study completion, an average of 1 year.